Highlights Johnson & Johnson Bulgaria S.E.

Equities

JNJ

US4781601046

End-of-day quote Bulgaria S.E. Other stock markets 23:00:00 16/06/2024 BST			5-day change	1st Jan Change
136.2 ^EUR	-3.13%		-3.13%	-14.26%

06-20	Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	MT
06-20	Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	06-20	MT
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	06-20	CI
J&J: launches open, secure digital ecosystem	06-20	CF
J&J: promising results in Crohn's disease	06-20	CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	06-20	MT
Johnson & Johnson Sees Positive Trial Results for Tremfya	06-20	DJ
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	06-17	CI
J&J: positive results in Sjögren's disease	06-17	CF
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints	06-17	MT
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study	06-15	CI
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE
J&J: encouraging trial in relapsing multiple myeloma	06-14	CF
J&J: the promise of ibrutinib in CLL	06-14	CF
J&J: promising results for Imbruvica in leukemia	06-14	CF
Johnson & Johnson Reports Positive Long-Term Results for Talvey in Multiple Myeloma Study	06-14	MT
Johnson & Johnson Announces TALVEY® (Talquetamab-Tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma	06-14	CI
High-risk health workers can get routine Ebola vaccine, Gavi says	06-13	RE
Xencor to Regain Exclusive Global Rights to CD20 x CD3 Bispecific T-Cell Engager	06-13	MT
High-risk health workers can get routine Ebola vaccine, says Gavi	06-13	RE
Cancer victims ask court to block J&J talc bankruptcy	06-12	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm